Evidence map›Paper›PMID 42794882›Full record

ArticleCancers2026

Changes in C-Reactive Protein Forecast Infection Risk Following Treatment with Chimeric Antigen Receptor T Cells.

Poonam Mathur, Hegang Chen, David J Riedel, Elizabeth Holland, Danica Palacio, Jacqueline T Bork, Katya Prakash, Nancy Hardy, Mehmet Kocoglu, Ashraf Badros and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Poonam MathurInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0003-1346-9388
Hegang ChenInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
David J RiedelInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-7399-6406
Elizabeth HollandInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Danica PalacioPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2505-377X
Jacqueline T BorkInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-1546-6634
Katya PrakashZucker School of Medicine, Northwell Health, Manhasset, NY 11030, USA.ORCID 0000-0002-8653-4657
Nancy HardyInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Mehmet KocogluInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-9888-5737
Ashraf BadrosInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Ariel FromowitzInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jean YaredInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Aaron P RapoportInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Djordje AtanackovicInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
John BaddleyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunosuppressive conditioning regimens for chimeric antigen receptor-modified T cell immunotherapy (CARTx) and subsequent T cell dysfunction increase risk for infection. However, it is difficult to discern infection from CRS in the early (up to Day 30) and late (Days 31-180) periods after CARTx due to overlapping signs and symptoms.

methodsWe analyzed infectious complications and predictors of infection during the early and late periods after CARTx in 213 adult patients with malignancies over a 5-year period.

resultsOverall, 75 patients (35%) had at least one infection, mostly within the first 30 days after CARTx. Infections occurring early after CARTx were mostly bacterial, whereas viral infections predominated after Day 30. In multivariate analyses, a high baseline CRP (≥5 mg/dL) was significantly associated with increased risk of infection in the early period after CARTx, and a Day-5-to-baseline-CRP ratio of <1.5 was significantly associated with a higher risk of infection through all 180 days after CARTx and during the late period after CARTx.

conclusionsInfections in adult patients are common up to 180 days after receiving CARTx. High baseline CRP without significant temporal changes may predict risk of infection. Tracking CRP trends may be a useful clinical tool for discerning causes of fever and guiding antibiotic stewardship in this population at high risk for infections.

Indexed as

CAR-TCRPinfection

Identifiers

PMID42794882
PMCPMC13604072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.